Prot# CSL842_3001: A Double-Blind, Randomized-Withdrawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-Esterase Inhibitor as Add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection